Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
206
天
Distinct Trajectories of Patient-reported Outcome Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy: A Prospective Longitudinal Study
作者
Yanhong Zhou; Xiaomeng Lu; Wenhui Geng; Fengxia Liu; Lei Li; Jiahui Liu展开收起
作者单位
Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China; Department of Nursing, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China展开收起
136
天
Acute Radiation Dermatitis and Recovery After Ultra-hypofractionated Versus Hypofractionated Whole-breast Radiation Therapy: A Retrospective Cohort Study
作者
Samantha Juang; Julia Neiswander; Ashwin Ragupathi; Jasky Karem; Rosario Campo; Xueqing Huang; Dong Zhang; Maria Plummer; Rajasree Roy; Edward Obedian展开收起
作者单位
Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY; Department of Computer Sciences, College of Engineering and Computing Sciences, New York Institute of Technology, Old Westbury, NY; Center for Cancer Research, New York Institute of Technology, Old Westbury, NY; Department of Clinical Specialties, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY; St. Francis Hospital and Heart Center, The Cancer Institute, East Hills, NY展开收起
44
天
Prognostic Value of Baseline Metabolic Tumor Volume on [18F]FDG PET/CT in Metastatic Breast Cancer Treated With CDK4/6 Inhibitors
作者
Seyma Erdogan; Yusufcan Yılmaz; Elif Reyhan Aslan; Refia Yukselturk; Efnan Algın; Berna Okudan; Osman Inan; Oznur Bal展开收起
作者单位
Department of Internal Medicine, Health Science University, Ankara City Hospital, Ankara, Turkey; Department of Nuclear Medicine, Health Science University, Ankara City Hospital, Ankara, Turkey; Department of Medical Oncology, Health Science University, Ankara City Hospital, Ankara, Turkey展开收起
79
天
Clinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy
作者
Hannah M. Linden; Sophia R. O’Brien; Stephanie M. van de Ven; Paul La Porte; Peter S. Conti; Parvin F. Peddi; Joanne E. Mortimer; Christiana Brenin; Amol M. Takalkar; Julia E. McGuinness; Edgar Cheng; Amol Rao; Lanell M. Peterson; Jennifer M. Specht; Terence Z. Wong; David A. Buck; Adam M. Brufsky; Gary A. Ulaner展开收起
作者单位
Department of Medicine, Division of Hematology/Medical Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA; GE HealthCare, Pharmaceutical Diagnostics Research and Development, San Diego, CA; Medical Oncology, The Oncology Institute, CA; Department of Radiology, Molecular Imaging Center, Keck School of Medicine, University of Southern California, Los Angeles, CA; Margie Petersen Breast Center, Providence Saint John’s Cancer Institute, Santa Monica, CA; Department of Medical Oncology, City of Hope, Duarte, CA; Division of Hematology/Oncology, University of Virginia, Charlottesville, VA; Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA; Department of Medicine, Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center, NY; Nuclear Medicine, St. Luke's University Health Network, Bethlehem, PA; Hematology-Oncology, MemorialCare Cancer Institute, Fountain Valley, CA; Division of Nuclear Medicine and Radiotheranostics, Department of Radiology, Duke Health, Durham, NC; Radiation Oncology, Blue Ridge Cancer Care, Roanoke, VA; Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA; Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, California and Departments of Radiology and Cancer Biology, University of Southern California, Los Angeles, CA展开收起
24
天
Incidence and Treatment Patterns of Pleomorphic Lobular Carcinoma in Situ: A Population-based Analysis After the Introduction of ICD-O-3 Code 8519/2
作者
İsmail Zihni; Mehmet Zafer Sabuncuoğlu展开收起
作者单位
Department of General Surgery, Faculty of Medicine, Akdeniz University, Antalya, Türkiye展开收起
61
天
The Effect of Germline Pathogenic Variants in the Upgrade Rate to Breast Cancer Among Patients Diagnosed With Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ on Core Needle Biopsy
作者
Komal Ijaz; Broden Alston; Therese Bevers; Banu Arun; Diane Weber; Min Yi; Kelly Hunt; Gary Whitman; Lavinia P. Middleton展开收起
作者单位
Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX展开收起
FAQ
Clinical Breast Cancer审稿要多久?
截至2026-11-14,CrushSCI 收录了 Clinical Breast Cancer 的 15 篇完整审稿记录。最快一篇从收稿到录用用了 4 天(Intraoperative and Perioperative Outcomes of Breast-Conserving Surgery After Neoadjuvant Systemic Therapy: A Retrospective Cohort Study,2026-08-06 收稿,2026-08-10 录用),最慢一篇用了 296 天;平均 87.3 天,中位数 79 天。最快这篇的日期间隔异常短,建议点开原文核对。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
